In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey

References

• Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th edn. Churchill Livingstone; 2010 pp 2921–5.
   Google Scholar
• Doganay M, Aygen B. Human brucellosis: an overview. Int J Infect Dis 2003;7:173–82.
   Google Scholar
• Cellillo C, Gotuzzo E. Brucellosis. In: Schlossberg D, editor. Current therapy of infectious diseases, 2nd edn, Mosby; 2001 pp 471–4.
   Google Scholar
• Doganay M, Mese EA. Brucellosis. In: Topcu AW, Soyletir G, Doganay M, editors. Infectious diseases and microbiology, 3rd edn. Nobel Medical Bookstores; 2008 pp. 897–909.
   Google Scholar
• Gotuzzo E, Carrillo C. Brucella. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases, 2nd edn. Saunders Co.; 1998 pp 1837–45.
   Google Scholar
• Garcia-Rodriguez JA, Garcia Sanchez JE, Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother 1991; 35:756–9.
   PubMedGoogle Scholar
• Akova M, Uzun O, Akalın HE, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993;37:1831–4.
   PubMed Web of Science ®Google Scholar
• Joint Food and Agriculture Organization/World Health Organization. FAO-WHO Expert Commitee on brucellosis, sixth report. WHO technical report series no: 740. World Health Organization; 1986 pp 56–7.
   Google Scholar
• Lang R, Rubinstein E. Quinolones for the treatment of brucellosis. J Antimicrob Chemother 1992;29:357–63.
   PubMedGoogle Scholar
• Kocagoz S, Akova M, Altun B, Gur D, Hascelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002;8:240–2.
   PubMed Web of Science ®Google Scholar
• Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia Rodriguez JA. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999;43: 194–5.
   PubMed Web of Science ®Google Scholar
• Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Torres Y, Gutierrez-Rubio A, et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004;36:636–8.
   PubMedGoogle Scholar
• Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I, Garcia-Sanchez E, Garcia Garcia MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995;39:1194–5.
   PubMedGoogle Scholar
• Yamazhan T, Aydemir S, Tunger A, Serter D, Gokengin D. In vitro activities of various antimicrobials against Brucella melitensis species in the Aegean region in Turkey. Med Princ Pract 2005;14:413–16.
   PubMed Web of Science ®Google Scholar
• Kilic S, Dizbay M, Cabadak H. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis. J Chemother 2008;20:33–7.
   PubMed Web of Science ®Google Scholar
• Aliskan H, Turunc T, Demiroglu YZ, Colakoglu S, Arslan H. Investigation of in vitro antibiotic susceptibility of Brucella melitensis. Mikrobiyol Bul 2008;42:125–9.
   PubMedGoogle Scholar
• İlhan Z, Solmaz H, Ekin IH. In vitro antimicrobial susceptibility of Brucella melitensis isolates from sheep in an area endemic for human brucellosis in Turkey. J Vet Med Sci 2013;75:1035–40.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother 2006;50:22–33.
   PubMed Web of Science ®Google Scholar
• Jiang H, Mao LL, Zhao HY, Li LY, Piao DR, Yao WQ, et al. MLVA typing and antibiotic susceptibility of Brucella human isolates from Liaoning, China. Trans R Soc Trop Med Hyg 2010;104:796–800.
   PubMedGoogle Scholar
• Heo EJ, Kang SI, Kim JW, Her M, Cho D, Cho YS, et al. In vitro activities of antimicrobials against Brucella abortus isolates from cattle in Korea during 1998-2006. J Microbiol Biotechnol 2012;22:567–70.
   PubMedGoogle Scholar
• Landinez R, Linares J, Loza E, Martinez-Beltran J, Martin R, Baquero F. In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Brucella melitensis. Eur J Clin Microbiol Infect Dis 1992;11:265–7.
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez JA, Munoz Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993;37:911–13.
   PubMed Web of Science ®Google Scholar
• Gur D, Kocagoz S, Akova M. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999;43:2337.
   PubMed Web of Science ®Google Scholar
• Moyer N, Holcomb L. Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 6th edn. American Society for Microbiology Press; 1995 pp 549–55.
   Google Scholar
• Bricker BJ, Halling SM. Differentiation of Brucella abortus bv. 1, 2 and 4, Brucella melitensis, Brucella ovis and Brucella suis bv. 1 by PCR. J Clin Microbiol 1994;32:2660–6.
   PubMed Web of Science ®Google Scholar
• Hall WH, Khan MY. Brucellosis. In: Hoeprich PD, Jordan MC, editors. Infectious diseases, 4th edn. JB Lippincott; 1989 pp 1282–8.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, vol. 29; 19th international supplement. M100-S19-MIC. CLSI; 2009.
   Google Scholar
• Guler L, Gunduz K, Ok U. Comparison of polymerase chain reaction and bacteriological culture for the diagnosis of sheep brucellosis using aborted fetus samples. Vet Microbiol 2003;93:53–61.
   PubMed Web of Science ®Google Scholar
• Bodur H, Balaban N, Aksaray S, Yetener V, Akıncı E, Colpan A, et al. Biotypes and antimicrobial susceptibility of Brucella isolates. Scand J Infect Dis 2003;35:337–8.
   PubMed Web of Science ®Google Scholar
• Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990;12:1060–99.
   PubMedGoogle Scholar
• Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 2005;35:210–12.
   PubMedGoogle Scholar
• Hashemi SH, Gachkar L, Keramat F, Mamani M, Hajilooi M, Janbakhsh A, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis 2012;16:247–51.
   Google Scholar
• Pappas G, Christou L, Akritidis N, Tsianos EV. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect 2006;12:823–5.
   PubMed Web of Science ®Google Scholar
• Khan MY, Dizon M, Kiel FW. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother 1989;33:1409–10.
   PubMedGoogle Scholar
• Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991;35:1925–7.
   PubMed Web of Science ®Google Scholar
• Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004;23:405–7.
   PubMed Web of Science ®Google Scholar
• Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, et al. Antimicrobial susceptibilities of Brucella isolates from various clinical speciemens. Int J Med Sci 2011;8:198–202.
   PubMedGoogle Scholar
• Parlak M, Guducuoglu H, Bayram Y, Cikman A, Aypak C, Kilic S, et al. Identification and determination of antibiotic susceptibilities of Brucella species isolated from patients in Van, Turkey by conventional and molecular methods. Int J Med Sci 2013;10:1406–11.
   PubMedGoogle Scholar
• Maves RC, Castillo R, Guillen A, Espinosa B, Meza R, Espinoza N, et al. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. Antimicrob Agents Chemother 2011;55:1279–81.
   PubMedGoogle Scholar
• Loza E, Martinez-Beltran J, Baquero F, Leon A, Canton R, Garijo B. Comparative in vitro activity of clarithromycin. Eur J Clin Microbiol Infect Dis 1992;11:856–66.
   PubMedGoogle Scholar